Skip to content

Article

Lipton Teas TLB SteerCo Launches Co-Op via Gibson Dunn; Uptake Exceeds 60%

✨ Summary by AI at Octus
Lenders to Lipton Teas and Infusion, fka Ekaterra, have formed a steering committee, or SteerCo and launched a cooperation agreement via law firm Gibson Dunn. The uptake currently exceeds 60% of the term loan B lenders, sources told Octus.

Lenders to Lipton Teas and Infusion, fka Ekaterra, have formed a steering committee, or SteerCo, and launched a cooperation agreement via law firm Gibson Dunn. The uptake currently exceeds 60% of the term loan B lenders, sources told Octus.

Given the recent liquidity boost the company received from sponsor CVC after a steep performance deterioration, there doesn’t appear to be any imminent trigger, but creditors are preemptively taking steps to organize in the event earnings do not recover quickly enough to enable Lipton Teas to refinance or amend and extend its debt down the line, sources noted.

After injecting €40 million of equity in November last year, sponsor CVC provided a further €210 million to shore up liquidity, consisting of a €160 million loan paying a 9% PIK margin and €50 million of additional equity.

The PIK loan was issued out of Ekaterra Group IP Holdings BV, which is a nonguarantor restricted subsidiary. It sits at the Opco level and ranks structurally ahead of the group’s TLB. Ekaterra’s intellectual property remains in the restricted group perimeter, sources earlier noted.

 

Performance Woes

Lipton Teas reported weak fourth-quarter 2025 results but earnings stabilized during the first quarter of 2026, as reported. Fourth-quarter 2025 net revenue fell 16% year over year to €371 million from €442 million the same quarter in 2024, driven by a 10% volume decline, while adjusted EBITDA fell 35% year over year to €85 million from €131 million the same period last year. First-quarter 2026 net revenue fell 9% year over year to €333 million from €365 million the same quarter in 2025, driven by a 3% volume decline, but adjusted EBITDA was flat versus the prior year quarter at €57 million.

The group generated €8 million of free cash flow during the fourth quarter of 2025, but burned €100 million during the course of the year, and burned another €38 million of cash during the first quarter this year, which left it with €96 million of liquidity comprising €89 million of cash and €7 million remaining under its almost fully drawn €375 million RCF.

The RCF is subject to a 9.5x senior secured net leverage test when more than 40% is drawn. Lipton reported 11.4x net leverage based on €280 million LTM EBITDA adjusted end-state EBITDA. Actual net leverage based on €252 million LTM adjusted EBITDA was 12.7x.

Lipton is budgeting growing full-year 2026 revenue 3.5% to €1.435 billion from €1.386 billion in 2025, and adjusted EBITDA to improve to €280 million from €252 million with margins rising to 19.5% from 18.2%. That would more than halve the group’s cash burn to about €46 million in 2026.

Management also announced to lenders a new business plan this week developed by the new management team under CEO Marc Busain that addresses Lipton’s past issues and accelerates development to drive strong future growth. Management’s base case projection is 5% compound annual growth rate for revenues by 2029 and margins of 22-24%, which would translate into around €380 million of adjusted EBITDA.
 

Lipton Teas and Infusion
 
03/31/2026
 
EBITDA Multiple
(EUR in Millions)
Amount
Price
Mkt. Val.
Maturity
Rate
Yield
Book
Market
 
€375M RCF
368.0
 
368.0
Dec-2028
EURIBOR + 3.250%
 
 
EUR TLA (€175M)
175.0
 
175.0
Jun-2029
EURIBOR + 6.500%
 
 
EUR TLB (€1.575B) 1
1,710.0
 
1,710.0
Jun-2029
EURIBOR + 4.750%
 
 
GBP TLB (£438M)
501.0
 
501.0
Jun-2029
SONIA + 5.625%
 
 
Total Senior Debt
2,754.0
 
2,754.0
 
12.8x
12.8x
AUD 2L (A$716M) 2
428.0
 
428.0
Jun-2030
Reference Rate + 7.750%
 
 
Short & Long term local facilities
107.0
 
107.0
 
 
 
 
Total Second Lien Debt
535.0
 
535.0
 
15.2x
15.2x
Total Debt
3,289.0
 
3,289.0
 
15.2x
15.2x
Less: Cash and Equivalents
(89.0)
 
(89.0)
 
Plus: Restricted Cash
7.0
 
7.0
 
Net Debt
3,207.0
 
3,207.0
 
14.8x
14.8x
Operating Metrics
LTM Revenue
1,340.0
 
LTM Reported EBITDA
216.0
 
 
Liquidity
RCF Commitments
375.0
 
Less: Drawn
(368.0)
 
Plus: Cash and Equivalents
89.0
 
Less: Restricted Cash
(7.0)
 
Total Liquidity
89.0
 
Credit Metrics
Gross Leverage
15.2x
 
Net Leverage
14.8x
 
Notes:
Capital structure is post-IFRS 16. Lipton reported 11.4x net leverage based on €280M LTM EBITDA Adjusted End State EBITDA
1. Increased by €135M during the fourth quarter 2024
2. The reference rate is BBSW.

This publication has been prepared by Octus Intelligence, Inc. or one of its affiliates (collectively, "Octus") and is being provided to the recipient in connection with a subscription to one or more Octus products. Recipient’s use of the Octus platform is subject to Octus Terms of Use or the user agreement pursuant to which the recipient has access to the platform (the “Applicable Terms”). The recipient of this publication may not redistribute or republish any portion of the information contained herein other than with Octus express written consent or in accordance with the Applicable Terms. The information in this publication is for general informational purposes only and should not be construed as legal, investment, accounting or other professional advice on any subject matter or as a substitute for such advice. The recipient of this publication must comply with all applicable laws, including laws regarding the purchase and sale of securities. Octus obtains information from a wide variety of sources, which it believes to be reliable, but Octus does not make any representation, warranty, or certification as to the materiality or public availability of the information in this publication or that such information is accurate, complete, comprehensive or fit for a particular purpose. Recipients must make their own decisions about investment strategies or securities mentioned in this publication. Octus and its officers, directors, partners and employees expressly disclaim all liability relating to or arising from actions taken or not taken based on any or all of the information contained in this publication. © 2026 Octus. All rights reserved. Octus(TM) and the Octus logo are trademarks of Octus Intelligence, Inc.